The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed

What Was Tested

The paper reports a study of Ghrelin, published as a clinical trial.

The aims of this study were to determine the effects of modifying the length of small intestine exposed to glucose on plasma concentrations of GLP-1 and also glucose-dependent insulinotropic peptide (GIP), insulin, cholecystokinin (CCK) and ghrelin, and antropyloric pressures.

Why It Was Studied

Glucose was infused at 3.5 kcal/min into the duodenum of eight healthy males (age 18-59 yr) over 60 min on the first day into an isolated 60-cm segment of the proximal small intestine ("short-segment infusion"); on the second day, the same amount of glucose was infused with access to the entire small intestine ("long-segment infusion").

Who Took Part

The age groups tagged for this paper are teenagers, adults and middle-aged adults, men only.

How the Study Was Run

In design terms this was a single-blind study.

In this single-blind Ghrelin study one party knew the assignments and the other did not.

What Was Measured

Glucose was infused at 3.5 kcal/min into the duodenum of eight healthy males (age 18-59 yr) over 60 min on the first day into an isolated 60-cm segment of the proximal small intestine ("short-segment infusion"); on the second day, the same amount of glucose was infused with access to the entire small intestine ("long-segment infusion").

The subject headings attached to it are Blood Glucose, Cholecystokinin, Gastric Inhibitory Polypeptide, Ghrelin, Glucagon-Like Peptide 1, Glucose and Insulin.

What This Means in Plain Language

The paper is a single-blind study of Ghrelin.

The publication is from 2006 (American journal of physiology. Endocrinology and metabolism), a journal based in United States.

More context: the Ghrelin compound page, all human trials.